Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidone

Andrew Thompson; Christian Lavedan; Simona Volpi

doi:10.1016/j.psychres.2009.03.020

Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidone

Psychiatry Res. 2010 Feb 28;175(3):271-3. doi: 10.1016/j.psychres.2009.03.020. Epub 2009 Dec 31.

Authors

Andrew Thompson¹, Christian Lavedan, Simona Volpi

Affiliation

¹ Vanda Pharmaceuticals Inc., Rockville, MD, USA.

PMID: 20045196
DOI: 10.1016/j.psychres.2009.03.020

Abstract

Weight gain is a common side effect of antipsychotics, contributing to poor treatment adherence, and previously linked to the -759C/T polymorphism near the serotonin receptor 2C gene. The effect of this polymorphism was analyzed in schizophrenia patients treated with iloperidone for up to 7 months. No association was detected with the modest weight changes observed in these patients.

Publication types

Clinical Trial
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Analysis of Variance
Antipsychotic Agents / therapeutic use*
Female
Follow-Up Studies
Gene Frequency
Genotype
Humans
Isoxazoles / therapeutic use*
Male
Piperazines / therapeutic use
Piperidines / therapeutic use*
Polymorphism, Genetic / genetics*
Receptor, Serotonin, 5-HT2C / genetics*
Schizophrenia* / drug therapy
Schizophrenia* / genetics
Schizophrenia* / physiopathology
Thiazoles / therapeutic use
Weight Gain* / drug effects
Weight Gain* / genetics
Weight Gain* / physiology

Substances

Antipsychotic Agents
Isoxazoles
Piperazines
Piperidines
Receptor, Serotonin, 5-HT2C
Thiazoles
ziprasidone
iloperidone